bioMérieux and Hitachi High-Technologies Corporation Enter into Long-Term Strategic Partnership

bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics has entered into a long-term strategic partnership with Hitachi High-Technologies Corporation of Japan.

With this new strategic relationship, bioMérieux and Hitachi High-Technologies Corporation will become preferred partners to develop new microbiology and molecular diagnostic systems.

bioMérieux and Hitachi High-Technologies Corporation will work together to identify and develop new systems. The new instruments developed under this partnership will be manufactured by Hitachi High-Technologies Corporation and distributed through bioMérieux’s worldwide commercial network. Teams from bioMérieux and Hitachi High-Technologies Corporation are working together toward development milestones on a new system.

“bioMérieux’s vision, and a key objective of our 2012 strategy, is to bring full automation to microbiology laboratories around the world. This partnership enables bioMérieux to work with extremely talented engineers from Hitachi High-Technologies Corporation to better serve our customers,” declared Stéphane Bancel, Chief Executive Officer of bioMérieux. “We will also introduce innovative systems to molecular diagnostics, leveraging bioMérieux’s expertise in biology and Hitachi High-Technologies Corporation’s remarkable engineering capabilities,” he added.

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. In 2007, revenues reached €1.063 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Eurolist by Euronext. For more information, visit http://www.biomerieux.com/.

bioMérieux Contacts

Investor Relations

bioMérieux
Isabelle Tongio
Tel: + 33 4 78 87 22 37
investor.relations@eu.biomerieux.com

LT Value
Nancy Levain
Tel: + 33 1 44 50 39 30
nancy.levain@ltvalue.com

Media Relations

bioMérieux
Koren Wolman-Tardy
Tel: + 33 4 78 87 20 08
media@eu.biomerieux.com

Image Sept
Laurence Heilbronn
Tel: + 33 1 53 70 74 64
lheilbronn@image7.fr

Tiphaine Hecketsweiler
Tel: + 33 1 53 70 74 59
thecketsweiler@image7.fr